CC-220

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

LymphomaMultiple MyelomaSystemic Lupus ErythematosusMyelofibrosisSarcoidosisPolycythemia Vera

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

1

CC-220

Bristol-Myers Squibb

Phase 2

32

Velban

EEastern Cooperative Oncology Group

Preclinical

153

Zofran

Novartis

Preclinical

24

Norvir

AbbVie

Preclinical

15

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

46

Tafasitamab

Incyte

Preclinical

77

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

18

Nuvigil

NNuvo Research GmbH

Preclinical

19

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—Show 19 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Tics3 trials

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

Completed·Bristol-Myers Squibb·Phase 1·NCT02034773·64 enrolled

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Completed·Bristol-Myers Squibb·Phase 1·NCT01733875·65 enrolled

Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects

Completed·Bristol-Myers Squibb·Phase 1·NCT02820935·36 enrolled

Lymphoma3 trials

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Withdrawn·Bristol-Myers Squibb·Phase 1/2·NCT04882163

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Terminated·Bristol-Myers Squibb·Phase 1·NCT04464798·62 enrolled

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Recruiting·Bristol-Myers Squibb·Phase 1·NCT04884035·174 enrolled

Systemic Lupus Erythematosus2 trials

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Completed·Bristol-Myers Squibb·Phase 2·NCT03161483·289 enrolled

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

Completed·Bristol-Myers Squibb·Phase 2·NCT02185040·42 enrolled

Multiple Myeloma2 trials

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Active, not recruiting·Bristol-Myers Squibb·Phase 1/2·NCT02773030·466 enrolled

An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects With Relapsed/Refractory Multiple Myeloma (KarMMa-7)

Terminated·Bristol-Myers Squibb·Phase 1·NCT04855136·21 enrolled

Hepatic Impairment1 trial

Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects

Completed·Bristol-Myers Squibb·Phase 1·NCT03824678·40 enrolled

4 more indications

Adult Subject1 trial

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

Completed·Bristol-Myers Squibb·Phase 1·NCT03135509·16 enrolled

Relapsed/Refractory B-cell Malignancies1 trial

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Completed·Bristol-Myers Squibb·Phase 1/2·NCT03310619·62 enrolled

Sarcoidosis1 trial

A Phase 2 Study With CC-220 in Skin Sarcoidosis

Withdrawn·Bristol-Myers Squibb·Phase 2·NCT02192489

Unspecified1 trial

Radiolabeled Study of CC-220 in Healthy Male Subjects

Completed·Bristol-Myers Squibb·Phase 1·NCT03294603·6 enrolled

Details

Drug Info

Related News